

Table S1. ENO2 expression and clinicopathological features of CRC patients

	Positive (N=37) Number (%)	Negative (N=84) Number (%)	P-value
Gender			
Male	26 (70.3)	46 (54.8)	0.159
female	11 (29.7)	38 (45.2)	
Tumor characteristics			
tub1, tub2	34 (91.9)	80 (95.2)	0.436
por sig, muc	3 (8.1)	4 (4.8)	
Depth			
Tis, T1, T2	8 (21.6)	37 (44.0)	0.024
T3, T4	29 (78.4)	47 (56.0)	
Lymph node metastasis			
N0	17 (46.0)	60 (71.4)	0.013
N1, N2, N3	20 (54.0)	24 (18.6)	
Distant metastasis			
M0	31 (83.8)	81 (96.4)	0.023
M1	6 (16.2)	3 (3.6)	
Lymphatic duct invasion			
ly0	8 (21.6)	40 (47.6)	0.009
ly1, ly2	29 (78.4)	44 (52.4)	
Venous invasion			
V0	22 (59.5)	62 (73.8)	0.136
V1, v2	15 (40.5)	22 (26.2)	
Stage			
0, I, II	16 (43.2)	60 (71.4)	0.004
III, IV	21 (56.8)	24 (28.6)	
BRAF V600E			
Wild type	31 (83.8)	83 (98.8)	<0.05
Mutated type	6 (16.2)	1 (1.2)	

Abbreviations: tub1, well-differentiated tubular adenocarcinoma; tub2, moderately differentiated tubular adenocarcinoma; por, poorly differentiated adenocarcinoma; muc, mucinous adenocarcinoma.